Cytogen has canceled plans to acquire Advanced Magnetics and instead has signed a marketing and sales agreement for the rights to two Advanced Magnetics products.Advanced Magnetics of Cambridge, MA, will give Cytogen of Princeton, NJ, the U.S. rights to
Cytogen has canceled plans to acquire Advanced Magnetics and instead has signed a marketing and sales agreement for the rights to two Advanced Magnetics products.
Advanced Magnetics of Cambridge, MA, will give Cytogen of Princeton, NJ, the U.S. rights to Combidex, an MRI agent used for detection of lymph node metastases, and to Code 7228, Advanced Magnetics next-generation imaging agent.
In exchange, Advanced Magnetics received 1.5 million shares of Cytogen stock and will receive another half-million shares in milestone payments. Cytogen will pay Advanced Magnetics a royalty based on the products sales, when they are approved by the FDA.
Cytogen shares were basically unchanged the day after the new deal was announced (Aug. 28), falling 9¢ to $8.94. But Advanced Magnetics stock lost $2.44 to close at $5.13 a share.
Advanced Magnetics is halfway to an NDA approval for its MR contrast agent, Combidex. The FDA in July sent the company a letter saying that although it found Combidex approvable for its principal indication, as a lymph node imaging agent, it could not approve the agent for its secondary indication, imaging of the liver and spleen (SCAN 7/5/00).
Jerome Goldstein, chairman and CEO of Advanced Magnetics, said that Combidex is the first lymph-node-specific MR contrast agent to be filed with the FDA.
The firm submitted its new drug application for Combidex to the FDA in December 1999. Advanced Magnetics European marketing partner, Guerbet, submitted the European equivalent of an NDA to the European Medicines Evaluations Agency at the same time.
The company has incurred financial losses while waiting for approval to market this product.
Cytogen currently markets two imaging agents: ProstaScint for prostate cancer and OncoScint CR/O for colorectal and ovarian cancers.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.